The purpose of this guidance is to assist sponsors in the clinical development of drugs for treating idiopathic and diabetic gastroparesis. Specifically, this guidance addresses FDA’s current recommendations regarding clinical trial designs and clinical endpoint assessments to support developing gastroparesis drugs.

This draft guidance is intended to serve as a focus for continued discussions among the responsible FDA divisions in the Office of New Drugs, pharmaceutical sponsors, the academic community, and the public.